Christian Goldis

Mr. Christian Goldis


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
AGAdrian Goldiș
Adrian Goldiș
RDRadu Dragomir
Radu Dragomir
MMMarina Adriana Mercioni
Marina Adriana Mercioni
CGChristian Goldis
Christian Goldis
DSDiana Cristiana Sirca
Diana Cristiana Sirca
OBOana Belei
Oana Belei
Inflammatory bowel disease (IBD) is a complex disorder influenced by genetic, environmental, and microbial factors, with emerging evidence highlighting the gut microbiome’s role in disease pathogenesis. This study investigates the impact of microbiome-targeted interventions in pediatric IBD by integrating multi-omics analysis, including metagenomics, metabolomics, transcriptomics, and clinical biomarkers, to identify microbial dysbiosis patterns and potential therapeutic targets. A cohort of pediatric IBD patients underwent a personalized intervention involving dietary modifications, probiotic supplementation, and selective antibiotic therapy. Microbiome composition, inflammatory markers (fecal calprotectin, CRP), and disease activity scores (PCDAI/PUCAI) were assessed before and after treatment. At the 3-month follow-up, patients showed significant clinical improvement, with reduced stool frequency (p = 0.004) and improved stool consistency (p < 0.001). Symptoms such as bloating and abdominal pain decreased, while energy levels increased (p < 0.001). Dietary changes included higher fruit, meat, and dairy intake, and lower fast-food and sweets consumption (p < 0.001). Physician assessments classified 90% as “improved”, reinforcing the effectiveness of personalized microbiome interventions. Microbiome-targeted interventions (diet, probiotics, and selective antibiotics) improved pediatric IBD outcomes by reducing pathogenic bacteria and increasing short-chain fatty acid (SCFA)-producing species, lowering inflammation and symptoms. Early-life factors (cesarean birth, and formula feeding) influence IBD risk. Personalized diets enhanced microbial balance. Integrating multi-omics supports precision medicine, offering microbiome-based biomarkers and reducing immunosuppressive reliance.

26 March 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
AGAdrian Goldiș
Adrian Goldiș
RDRadu Dragomir
Radu Dragomir
MMMarina Adriana Mercioni
Marina Adriana Mercioni
CGChristian Goldis
Christian Goldis
DSDiana Cristiana Sirca
Diana Cristiana Sirca
OBOana Belei
Oana Belei
Background/Objectives: Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is characterized by chronic gut inflammation driven by microbial dysbiosis and immune dysfunction. Current therapies primarily involve anti-inflammatory and immunomodulatory strategies; however, many patients experience an inadequate response or a gradual loss of efficacy over time. This study evaluates the clinical efficacy of personalized microbiome modulation (PMM)—an AI-driven intervention designed to restore microbial balance and improve key treatment outcomes such as symptom control and remission rates. Methods: This was a single-arm, open-label validation trial involving 27 patients with moderate-to-severe IBD who had experienced prior treatment failure. Participants underwent three months of PMM, which included personalized dietary modifications, targeted probiotic supplementation, and antimicrobial interventions based on gut microbiome sequencing. Primary outcomes included stool frequency and consistency as well as inflammatory markers (C-reactive protein and fecal calprotectin), while secondary outcomes assessed nutritional status, metabolic function, and quality of life. Statistical analyses included paired t-tests and repeated measures ANOVA to determine significant changes over time. Results: PMM led to significant clinical improvements, including a 58% reduction in stool frequency (p < 0.001) and improved stool consistency. CRP and fecal calprotectin levels decreased markedly (p < 0.001), suggesting reduced systemic inflammation. Additionally, iron, vitamin B12, and vitamin D deficiencies improved (p < 0.001), alongside weight gain and increased energy levels. Notably, patients on anti-TNF biologics showed enhanced response rates, suggesting potential synergistic effects between microbiome modulation and biologic therapy. Conclusions: This study highlights PMM as a promising adjunctive therapy for IBD, demonstrating benefits across clinical, inflammatory, and metabolic parameters. While findings support the role of microbiome-targeted interventions in disease management, larger randomized controlled trials are required to confirm the long-term efficacy and applicability in broader patient populations.

9 January 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DTDenisia Adelina Tornea
Denisia Adelina Tornea
CGChristian Goldis
Christian Goldis
AIAlexandru Isaic
Alexandru Isaic
AMAlexandru Catalin Motofelea
Alexandru Catalin Motofelea
ASAlexandra Sima
Alexandra Sima
AGAdrian Goldis
Adrian Goldis
Background: Metabolically associated fatty liver disease (MASLD) constitutes a major burden. Glucagon-like peptide-1 agonists (GLP-1) could improve hepatic steatosis as well as weight loss. However, the effect of GLP-1 agonists on patients with and without diabetes and the effect of newer drugs (dual and triple agonists) are unclear. Objective: To investigate the effect of GLP-1 agonists, including dual and triple agonists, in patients with metabolic-associated liver steatosis and steatohepatitis, while exploring their effect on patients with and without type 2 diabetes. Methods: We searched PubMed, Scopus, and Web of Science in October 2025 for randomized parallel controlled trials that investigated the effect of GLP-1 agonists in patients with MASLD or metabolic-associated steatohepatitis (MASH). We assessed the quality of the included studies using Cochrane ROB2. We performed the analysis using RevMan 5.4. We performed subgroup analysis based on the status of diabetes, the control group, and the class of GLP-1 agonist (single, dual, or triple). Results: We included twenty studies. Compared to the control group, GLP-1 agonists were associated with a statistically significant increase in the resolution of MASH without worsening fibrosis (RR 3.03, p < 0.0001) and at least one stage of liver fibrosis without the worsening of MASH compared to the control group (RR: 1.45, p < 0.00001). GLP-1 agonists were associated with a statistically significant weight reduction (SMD −1.11, p < 0.0001), glycosylated hemoglobin (SMD −0.81, p < 0.00001), levels of aspartate aminotransferase (SMD −0.48, p = 0.008), and alanine aminotransferase (SMD −0.54, p = 0.008). However, in patients without type 2 diabetes, GLP-1 agonists had no significant effect on weight loss (SMD −0.97, p = 0.12) or improvement in fibrosis (RR 1.54, p = 0.24). There was a statistically significant increase in the overall adverse events (RR 1.10, p < 0.00001), while there was no significant difference in serious adverse events (p = 0.35). Conclusions: GLP-1 agonists improved liver fibrosis, steatohepatitis, weight loss, HbA1c, and liver enzymes in patients with MASLD or MASH. Overall, GLP-1 agonists were associated with a significantly higher risk of adverse events compared to the control, while serious adverse events were comparable between both groups. There was no significant effect on weight loss or improvement in fibrosis in patients without type 2 diabetes. However, there was a limited number of studies in this population. Thus, further research is needed before recommendations can be made for this subgroup.

31 May 2025 in Life
Verified
Journal Article
Open access
PDF file
AGAdrian Goldiș
Adrian Goldiș
RDRadu Dragomir
Radu Dragomir
MMMarina Adriana Mercioni
Marina Adriana Mercioni
DSDiana Cristiana Sirca
Diana Cristiana Sirca
CGChristian Goldis
Christian Goldis
OBOana Belei
Oana Belei
Background: Few studies have evaluated the efficacy of butyric acid in treating children with inflammatory bowel disease (IBD). In children and adolescents with recently diagnosed IBD, the purpose of this research was to assess the efficacy of oral sodium butyrate (the product-patented, sustained and targeted-release form of butyrate MSB®) as an adjunct to conventional treatment. Methods: This trial was unicentric, prospective, randomized, and placebo-controlled. An amount of 150 mg sodium butyrate once a day (Group A), or a placebo (Group B) were randomly assigned to patients with ulcerative colitis or Crohn’s disease, aged 7–18 years, who were receiving conventional medication based on the severity of their conditions. Disease activity, C-reactive protein (CRP), and fecal calprotectin concentration differences between the two study groups at 12 weeks of the trial were the main outcomes. Results: With 44 patients in Group A and 44 in Group B, 88 individuals with initially active illness finished the research. Most patients experienced remission by week 12 of the study (36 patients in Group A with sodium butyrate, 81.82%; 21 patients in Group B with placebo, 47.73%). Between the two groups, a significant difference in disease activity was seen (p < 0.001). The sodium butyrate group appeared to have less systemic inflammation than the other group, as evidenced by the significantly lower CRP levels in Group A (18.14 ± 11.19 mg/L) compared to Group B (57.00 ± 33.28 mg/L) at 12 weeks (T2) (p < 0.001). No negative effects were recorded by any of the patients. Fecal calprotectin in Group A dropped much more after 12 weeks (T2) (p < 0.001), suggesting that the sodium butyrate group was better able to regulate intestinal inflammation. Conclusions: In newly diagnosed children and adolescents with IBD, a 12-week sodium butyrate supplementation did demonstrate effectiveness as an additional treatment.

12 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MMMarina Adriana Mercioni
Marina Adriana Mercioni
AGAdrian Goldiș
Adrian Goldiș
NHNina Holban
Nina Holban
MPMihai Vasile Popescu
Mihai Vasile Popescu
RDRadu Dragomir
Radu Dragomir
OBOana Belei
Oana Belei
Background: Chronic inflammatory bowel diseases (IBDs), specifically Crohn’s disease and ulcerative colitis, present substantial clinical challenges characterized by a relapsing-remitting course. These conditions often lead to serious complications and significantly impair nutritional status, physical development, and overall quality of life. Methods: This unicentric, prospective, open-label, alternation-based comparative study investigated the efficacy of vitamin D3 supplementation in adolescents with IBD. Patients aged 15–25 years were randomly assigned to receive either 1000 IU/day or 2000 IU/day of cholecalciferol for 6 months as an adjuvant to standard care. Eighty patients completed the study. Results: By month 6, remission was achieved in 52.5% of patients receiving 1000 IU/day (Group A) and 87.5% of those receiving 2000 IU/day (Group B). Significant differences were observed between groups regarding disease activity (p = 0.007), C-reactive protein levels (30.17 ± 15.74 mg/L vs. 62.82 ± 37.14 mg/L; p < 0.001), and fecal calprotectin levels. Conclusions: The machine learning models demonstrated consistent performance in assessing inflammatory indicators, with a weighted average recall exceeding 72% (Random Forest: 82.50%). No adverse effects were reported. Supplementation with 2000 IU/day of vitamin D3 for 6 months was associated with more favorable clinical and biochemical outcomes than 1000 IU/day in this single-center open-label study as an adjunct to standard treatment in adolescents and young adults with IBD. The results suggest that higher doses of vitamin D may be beneficial in achieving remission and reducing systemic inflammation.

11 April 2026 in Molecules
Verified
Journal Article
Open access
PDF file
CGChristian Goldis
Christian Goldis
NPNicoleta Anamaria Pascalau
Nicoleta Anamaria Pascalau
Roxana Racoviceanu (Babuta)Roxana Racoviceanu (Babuta)
Roxana Racoviceanu (Babuta)
TMTamara Maksimovic
Tamara Maksimovic
MJMihaela Jorgovan
Mihaela Jorgovan
Codruta SoicaCodruta Soica
Codruta Soica
Rare-earth elements (REEs), which include the entire lanthanide series together with scandium and yttrium, have unique electronic configurations and coordination chemical properties that provide them with special magnetic, optical, and redox abilities. Generally used for diagnostic imaging and theranostic applications, increasing evidence emphasizes their potential as direct anticancer agents. This review aims to present a thorough investigation of the studies published in the last ten years that focus on the intrinsic anticancer properties of REE-based molecular complexes and nanostructures, without discussing their recognized imaging functions. Rare-earth compounds exhibit selective cytotoxicity against malignant cells via mechanisms that mainly include modulations in the generation of reactive oxygen species, mitochondrial dysfunctions, interaction with DNA molecules, apoptosis, and ferroptosis induction, as well as radiosensitization. Molecular complexes that are based on the trivalent coordination chemistry of REEs enable them to target biomolecules like DNA and serum albumin. Nanostructured systems, on the other hand, render tumors more responsive to treatment by improving the cellular uptake, enabling surface functionalization, and controlling ROS generation. Terbium, thulium, yttrium, scandium, ytterbium, cerium, erbium, dysprosium, and europium show different levels of anticancer activity in both in vitro and in vivo cancer models. They often exert more toxicity in tumor cells than in normal tissues, thus exhibiting selective anticancer effects. The findings collectively underscore the therapeutic potential of REE-based compounds as novel metal-based anticancer agents and advocate for additional mechanistic and translational research to enhance their clinical applicability.